Drug repurposing opportunities for chronic kidney disease
- PMID: 38947510
- PMCID: PMC11214293
- DOI: 10.1016/j.isci.2024.109953
Drug repurposing opportunities for chronic kidney disease
Abstract
The development of targeted drugs for the early prevention and management of chronic kidney disease (CKD) is of great importance. However, the success rates and cost-effectiveness of traditional drug development approaches are extremely low. Utilizing large sample genome-wide association study data for drug repurposing has shown promise in many diseases but has not yet been explored in CKD. Herein, we investigated actionable druggable targets to improve renal function using large-scale Mendelian randomization and colocalization analyses. We combined two population-scale independent genetic datasets and validated findings with cell-type-dependent eQTL data of kidney tubular and glomerular samples. We ultimately prioritized two drug targets, opioid receptor-like 1 and F12, with potential genetic support for restoring renal function and subsequent treatment of CKD. Our findings explore the potential pathological mechanisms of CKD, bridge the gap between the molecular mechanisms of pathogenesis and clinical intervention, and provide new strategies in future clinical trials of CKD.
Keywords: Bioinformatics.
© 2024 The Authors. Published by Elsevier Inc.
Conflict of interest statement
The author declared no conflicts of interest.
Figures





Similar articles
-
Mendelian randomization analysis identifies druggable genes and drugs repurposing for chronic obstructive pulmonary disease.Front Cell Infect Microbiol. 2024 Apr 10;14:1386506. doi: 10.3389/fcimb.2024.1386506. eCollection 2024. Front Cell Infect Microbiol. 2024. PMID: 38660492 Free PMC article.
-
HDL Cholesterol, LDL Cholesterol, and Triglycerides as Risk Factors for CKD: A Mendelian Randomization Study.Am J Kidney Dis. 2018 Feb;71(2):166-172. doi: 10.1053/j.ajkd.2017.06.011. Epub 2017 Jul 26. Am J Kidney Dis. 2018. PMID: 28754456
-
Identifying actionable druggable targets for breast cancer: Mendelian randomization and population-based analyses.EBioMedicine. 2023 Dec;98:104859. doi: 10.1016/j.ebiom.2023.104859. Epub 2023 Oct 28. EBioMedicine. 2023. PMID: 38251461 Free PMC article.
-
Recent advances in the application of Mendelian randomization to chronic kidney disease.Ren Fail. 2024 Dec;46(1):2319712. doi: 10.1080/0886022X.2024.2319712. Epub 2024 Mar 4. Ren Fail. 2024. PMID: 38522953 Free PMC article. Review.
-
Genome-Wide Association Studies of CKD and Related Traits.Clin J Am Soc Nephrol. 2020 Nov 6;15(11):1643-1656. doi: 10.2215/CJN.00020120. Epub 2020 May 14. Clin J Am Soc Nephrol. 2020. PMID: 32409295 Free PMC article. Review.
Cited by
-
Identification of Therapeutic Targets for Hyperuricemia: Systematic Genome-Wide Mendelian Randomization and Colocalization Analysis.Biomedicines. 2025 Apr 23;13(5):1022. doi: 10.3390/biomedicines13051022. Biomedicines. 2025. PMID: 40426853 Free PMC article.
-
Discovery and prioritization of genetic determinants of kidney function in 297,355 individuals from Taiwan and Japan.Nat Commun. 2024 Oct 29;15(1):9317. doi: 10.1038/s41467-024-53516-7. Nat Commun. 2024. PMID: 39472450 Free PMC article.
References
-
- Johansen K.L., Garimella P.S., Hicks C.W., Kalra P.A., Kelly D.M., Martens S., Matsushita K., Sarafidis P., Sood M.M., Herzog C.A., et al. Central and peripheral arterial diseases in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2021;100:35–48. doi: 10.1016/j.kint.2021.04.029. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous